BiotechTV - News

Afleveringen

1. Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

   5 november 2026 · 15 min

   Afspelen
   CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting. Lees meer

2. From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada

   4 november 2026 · 20 min

   Afspelen
   Sofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies. Lees meer

3. Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC

   3 november 2026 · 11 min

   Afspelen

   CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.

4. After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

   29 oktober 2026 · 21 min

   Afspelen
   President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM. Lees meer

5. At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

   27 oktober 2026 · 23 min

   Afspelen

   CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.

6. London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system

   19 oktober 2026 · 14 min

   Afspelen
   CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies. Lees meer

7. Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1

   15 oktober 2026 · 12 min

   Afspelen

   CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.

8. At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research

   14 oktober 2026 · 20 min

   Afspelen

   They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.

9. Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

   7 oktober 2026 · 24 min

   Afspelen

   From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.

10. After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

    6 oktober 2026 · 27 min

    Afspelen
    He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out. Lees meer

Alle 494 afleveringen →